Of 24,503 patients with complete OS data, CDKN2A-DEL patients had the most FGA, MSI score and largest number of patients having metastatic disease, while those CDKN2A-DELMUT patients had the biggest TMB and mutation count (Table S1). This evidence concerns the gene CDKN2A and metastatic neoplasm.